Text size:

  • Small
  • Normal
  • Large
An Indian pharmacist receives prescriptions to prepare medicines at his store in Allahabad. The ruling means poor patients around the world will get continued access to cheap versions of lifesaving medicines.
An Indian pharmacist receives prescriptions to prepare medicines at his store in Allahabad. The ruling means poor patients around the world will get continued access to cheap versions of lifesaving medicines.

Novartis court ruling opens global door to cheap generic drugs

Seriously ill patients in India and throughout the developing world may be treated for a tenth of the cost after a landmark ruling yesterday by the Indian supreme court that has global significance. Samanth Subramanian reports

NEW DELHI // Seriously ill patients in India and throughout the developing world may be treated for a tenth of the cost after a landmark ruling yesterday by the Indian supreme court that has global significance.

Judges threw out an attempt by the Swiss pharmaceutical giant Novartis to patent an updated version of the cancer drug Glivec. "A repetitive patent is not permissible on the same drug," the judges ruled.

Campaigners for low-cost health care hailed the judgment, but Novartis and intellectual-property lawyers cautioned that it risked driving pharmaceutical multinationals out of India and curbing the development of new medicines.

The ruling is important worldwide because India's Dh95 billion generic drug industry supplies much of the cheap medicine used in the developing world. It would be seriously restricted if Indian law allowed global drug companies to extend the lifespan of patents by making minor changes to medicines.

Once a drug's patent expires, generic manufacturers can legally produce it. They are able to make drugs at a fraction of the original manufacturer's cost because they do not carry out the expensive research and development.

The Indian generic drug manufacturer Cipla, for instance, makes a version of Glivec for less than a tenth of the original's selling price, which is at least 120,000 rupees (Dh8,135) for a month's supply.

"This is a big day for us," said Kiran Hukku, director of the Delhi branch of the non-profit Cancer Patients Aid Association. "Last year, we were able to supply only 5,000-odd doses of Glivec to people we were helping. This year, with more generics, I'm sure we'll do much better."

Glivec was the Swiss company's bestselling drug last year, with sales worth about Dh17bn. Novartis has been fighting for the patent since 2006, and lost two lower-court appeals along the way.

India's courts and patent offices have, in the recent past, concentrated on enabling cheaper versions of blockbuster drugs to come on to the market.

Last year, Natco Pharma, which manufactures a generic version of Glivec, was allowed to analyse Bayer AG's Nexavar, another anti-cancer drug. Also last year, Pfizer, Roche and Merck lost patents on various drugs in their stables on the ground that they were not sufficiently innovative.

Novartis seemed to have expected the court's decision to go against it. Last week, Paul Herrling, head of tropical disease research at Novartis, said: "Looking at recent cases, the mood in India makes it more likely that we would have a more negative response."

The Glivec case has reflected the larger debate in pharmaceuticals, of public interest versus intellectual property rights.

Medecins Sans Frontieres, the international medical charity, said before the verdict that a Novartis victory would ensure that "more and more treatments will remain priced out of reach for the duration of the patent term - 20 years or more - including those that are merely new forms of existing medicine and didn't deserve a patent in the first place."

In the short run, the benefits of lower drug costs are clear in India, where about 400 million people live below the globally accepted poverty line.

However, Saikrishna Rajagopal, an intellectual-property lawyer in New Delhi, said: "There's a great deal of concern in the industry that we're granting a premium to what is essentially copying."

Mr Rajagopal pointed out that, in a country such as the United States, a drug company could win swift relief and financial damages if its patent were infringed. In India, he said, cases dragged on for years, during which time local companies made their money by selling generics.

At the end of the litigation, even if the company won its claim, it received no financial damages. "There's no culture of awarding damages here. There's no treasure chest at the end of the rainbow."

As a result, he said, small drug manufacturers, instead of investing in research and development, are content to just make generics, often of poor quality.

But Ms Hukku said the Cancer Patients Aid Association had been happy with the quality of cancer generics. "The government's quality control process is quite good," she said.

Aditya Dev Sood, founder and chief executive of the Centre for Knowledge Societies in New Delhi, which consults on innovation, said it was a myth that patent-based protections were the "only way to incentivise innovation".

"The health of the public is both a public and a private good, which may merit special protections and exceptions," Mr Sood said.

"Moreover, it is an area where our ethical obligations to one another as fellow humans may have to trump existing legal standards, including intellectual property protections."


twitter: For breaking news from the Gulf, the Middle East and around the globe follow The National World. Follow us

Back to the top

More articles

Editor's Picks

 Iranian President Hassan Rouhani greets supporters after his arrival in Zahedan, the regional capital of Sistan and Baluchestan province on Tuesday, April 15, 2014. During Mr Rouhani's two-day visit, he will tour several other cities and hold meetings with local scholars and entrepreneurs. Maryam Rahmanian for The National

On the road with Hassan Rouhani

Iran's president is touring some of Iran's most underdeveloped provinces. Foreign correspondent Yeganeh Salehi is traveling with him.

 The Doha-based Youssef Al Qaradawi speaks to the crowd as he leads Friday prayers in Tahrir Square in Cairo, Egypt in February, 2011. The outspoken pro-Muslim Brotherhood imam has been critical of the UAE’s policies toward Islamist groups, adding to friction between Qatar and other GCC states. Khalil Hamra / AP Photo

Brotherhood imam skips Doha sermon, but more needed for GCC to reconcile

That Youssef Al Qaradawi did not speak raises hopes that the spat involving Qatar and the UAE, Saudi Arabia and Bahrain might be slowly moving towards a resolution.

 Twitter photo of  Abdel Fattah El Sisi on the campaign trail on March 30. Photo courtesy-Twitter/@SisiCampaign

El Sisi rides a bicycle, kicks off social media storm

The photos and video created a huge buzz across social media networks, possibly a marker of a new era for Egypt.

 An Afghan election commission worker carries a ballot box at a vote counting centre in Jalalabad on April 6. A roadside bomb hit a truck carrying full ballot boxes in northern Afghanistan, killing three people a day after the country voted for a successor to President Hamid Karzai. Eight boxes of votes were destroyed in the blast, which came as the three leading candidates voiced concerns about possible fraud. Noorullah Shirzada / AFP Photo

Two pressing questions for Afghanistan’s future president

Once in office, the next Afghan president must move fast to address important questions that will decide the immediate future of the country.

 Friday is UN Mine Awareness Day and Omer Hassan, who does demining work in Iraqi Kurdistan, is doing all he can to teach people about the dangers posed by landmines. Louise Redvers for The National

A landmine nearly ended Omer’s life but he now works to end the threat of mines in Iraq

Omer Hassan does demining work in Iraqi Kurdistan and only has to show people his mangled leg to underscore the danger of mines. With the world marking UN Mine Awareness Day on Friday, his work is as important as ever as Iraq is one of the most mine-affected countries in the world.

 Supporters of Turkey's ruling AKP cheer as they follow the election's results in front of the party's headquarters in Ankara on March 30. Adem Altan/ AFP Photo

Erdogan critic fears retaliation if he returns to Turkey

Emre Uslu is a staunch critic of Turkey's Prime Minister Recep Tayyip Erdogan. Now, with a mass crackdown on opposition expected, he is unsure when he can return home.


To add your event to The National listings, click here

Get the most from The National